Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
456
¥ millions (change in business revenue in fiscal 2026)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales+52.2%
基準 874Target1,330millions (fiscal 2025 results → fiscal 2026 plan, business revenue)
Operating profit-98.8%
基準 -5,145Target-10,230millions (fiscal 2025 results → fiscal 2026 plan, operating income/loss)
Net income for the current fiscal year-100.1%
基準 -5,123Target-10,250millions (fiscal 2025 results → fiscal 2026 plan)
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous plan¥880 millions (fiscal 2025 business revenue outlook → actual results) → ¥874 millions (fiscal 2025 business revenue outlook → actual results)-0.7%Calculated from the two disclosed figures
Investment amount by sectorField Research and development costs to maximize the global product value of the HGF gene therapy drug / Amount expected to be raised ¥3,087 million / Amount already allocated ¥555 million, Field Costs for expanding ACRL's contracted testing business / Amount expected to be raised ¥590 million / Amount already allocated ¥0 million, Field Costs for relocating EmendoBio's research and development site / Amount expected to be raised ¥1,000 million / Amount already allocated ¥0 million, Field Working capital, including other research and development costs / Amount expected to be raised ¥2,244 million / Amount already allocated ¥3 million
Key initiatives
01Strengthen efforts targeting rare genetic diseases
02Promoting Global Expansion
03Continuously expand the pipeline
04Maximize the value of the HGF gene therapy product
05Deepen and expand the technology platform
06Strengthen the organization, talent and functions of the overseas division and overseas subsidiaries
07Strengthen the organization and develop talent for globalization
Non-financial targetsIndicator Number of expanded newborn screening tests contracted to ACRL / Target value 90,000 tests/year / Timing FY2025, Indicator Enrollment in the domestic Phase II clinical trial of NF-κB decoy oligodeoxyribonucleic acid / Target value Enrollment completed / Timing During 2026, Indicator Additional enrollment in the early Phase II clinical trial of the Tie2 receptor agonist / Target value Aim to complete enrollment / Timing First quarter of 2026
Size of the Target MarketMarket Gene therapy drugs (global) / Scale US$13.65 billion in 2025 and US$62.85 billion in 2032 / Growth rate CAGR 29.9% / Source https://www.intelmarketresearch.com/gene-therapy-market-22330, Market Nucleic acid drugs (global) / Scale US$2.1 billion in 2018 and US$19.4 billion in 2030 (more than 9 times the 2018 level) / Growth rate Not disclosed / Source Not disclosed, Market Regenerative medicine and gene therapy (all companies) / Scale Graph showing ¥3.8 trillion in 2020, ¥7.5 trillion in 2025, ¥10 trillion in 2030, ¥12 trillion in 2035 and approximately ¥15 trillion in 2040 / Growth rate Not disclosed / Source Prepared by Arthur D. Little based on the ADL database, Market Cancer (global/Japan) / Scale ¥2.9 trillion/¥510 billion in 2030 and ¥3.1 trillion/¥640 billion in 2040 / Growth rate Not disclosed / Source Analysis by Arthur D. Little based on the drug development product database
Risks identified by the company
Research and development
The current status of gene therapy and business development
The practical application of genome editing
Material events and other matters concerning the going-concern assumption
| Item | Details |
|---|---|
| Plan name | Disclosure of Matters Concerning Business Plans and Growth Potential |
| Plan period | 2022–2030 (growth strategy timeframe) / fiscal 2026 (full-year earnings plan) |
| Progress against the plan | Annual update |
| Sales Target | ¥874 millions (fiscal 2025 results → fiscal 2026 plan, business revenue) → ¥1,330 millions (fiscal 2025 results → fiscal 2026 plan, business revenue) |
| Operating profit target | ¥-5,145 millions (fiscal 2025 results → fiscal 2026 plan, operating income/loss) → ¥-10,230 millions (fiscal 2025 results → fiscal 2026 plan, operating income/loss) |
| Net income target | ¥-5,123 millions (fiscal 2025 results → fiscal 2026 plan) → ¥-10,250 millions (fiscal 2025 results → fiscal 2026 plan) |
| Investment amount by sector | Field Research and development costs to maximize the global product value of the HGF gene therapy drug / Amount expected to be raised ¥3,087 million / Amount already allocated ¥555 million, Field Costs for expanding ACRL's contracted testing business / Amount expected to be raised ¥590 million / Amount already allocated ¥0 million, Field Costs for relocating EmendoBio's research and development site / Amount expected to be raised ¥1,000 million / Amount already allocated ¥0 million, Field Working capital, including other research and development costs / Amount expected to be raised ¥2,244 million / Amount already allocated ¥3 million |
| Non-financial targets | Indicator Number of expanded newborn screening tests contracted to ACRL / Target value 90,000 tests/year / Timing FY2025, Indicator Enrollment in the domestic Phase II clinical trial of NF-κB decoy oligodeoxyribonucleic acid / Target value Enrollment completed / Timing During 2026, Indicator Additional enrollment in the early Phase II clinical trial of the Tie2 receptor agonist / Target value Aim to complete enrollment / Timing First quarter of 2026 |
| Key initiatives | Strengthen efforts targeting rare genetic diseases, Promoting Global Expansion, Continuously expand the pipeline, Maximize the value of the HGF gene therapy product, Deepen and expand the technology platform, Strengthen the organization, talent and functions of the overseas division and overseas subsidiaries, Strengthen the organization and develop talent for globalization |
| Results under the previous plan | ¥880 millions (fiscal 2025 business revenue outlook → actual results) → ¥874 millions (fiscal 2025 business revenue outlook → actual results) |
| Size of the Target Market | Market Gene therapy drugs (global) / Scale US$13.65 billion in 2025 and US$62.85 billion in 2032 / Growth rate CAGR 29.9% / Source https://www.intelmarketresearch.com/gene-therapy-market-22330, Market Nucleic acid drugs (global) / Scale US$2.1 billion in 2018 and US$19.4 billion in 2030 (more than 9 times the 2018 level) / Growth rate Not disclosed / Source Not disclosed, Market Regenerative medicine and gene therapy (all companies) / Scale Graph showing ¥3.8 trillion in 2020, ¥7.5 trillion in 2025, ¥10 trillion in 2030, ¥12 trillion in 2035 and approximately ¥15 trillion in 2040 / Growth rate Not disclosed / Source Prepared by Arthur D. Little based on the ADL database, Market Cancer (global/Japan) / Scale ¥2.9 trillion/¥510 billion in 2030 and ¥3.1 trillion/¥640 billion in 2040 / Growth rate Not disclosed / Source Analysis by Arthur D. Little based on the drug development product database |
| Risks identified | Research and development, The current status of gene therapy and business development, The practical application of genome editing, Material events and other matters concerning the going-concern assumption |
| Publication date | March 2026 |
Items this document does not state (12)
Operating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planSegment targetPlan assumptionsReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of Zokinvy are expected to increase, the number of expanded newborn screening tests contracted to ACRL is expected to rise slightly, costs for preparing the US filing for the HGF gene therapy product are expected to increase, and drug substance manufacturing costs for the product are expected to be incurred.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.